Cue Inc., a San Diego, CA-based at-home device for tracking health information at the molecular level, received an investment from Dentsu Ventures Global Fund I, Dentsu (TOKYO: 4324; ISIN: JP3551520004)’s corporate venture capital fund.
The amount of the deal was not disclosed.
Led by CEO Ayub Khattak, Cue has developed a cube-shaped hardware device into which diagnostic cartridges are inserted to provide at-home analysis of healthcare data at the molecular level, together with a smartphone application that can manage the results of the analysis.
Through a small sample of blood, saliva or mucus that has been collected and added to a color-coded cartridge which is then inserted into the Cue hardware device, a user can track health indicators such as vitamin D, testosterone, inflammation, influenza and fertility.
After approval from the relevant authorities has been obtained, the company aims to launch the product in the EU and Hong Kong in the second quarter of 2016. It should be available in the U.S. sometime during 2016 and in Japan in 2017.